Viatris

Viatris

0Viatris is a global healthcare company that was formed in 2020 through the merger of Mylan and Upjohn, a division of Pfizer. The company's mission is to provide access to high-quality medicines to patients all over the world. Viatris operates in more than 165 countries and territories and has a diverse portfolio of products, services and capabilities, including branded and generic medicines, complex generics, biosimilars and over-the-counter remedies.

History

Viatris was officially formed on November 16, 2020, following the merger of Mylan, a global generic and specialty pharmaceuticals company, and Upjohn, a division of Pfizer that focuses on manufacturing and selling off-patent branded and generic medications. The merger was first announced in July 2019 and was completed after receiving regulatory approval from multiple countries.

Products and Services

Viatris has a broad portfolio of medicines, including both branded and generic drugs, complex generics, biosimilars and over-the-counter (OTC) remedies. The company's product portfolio spans a wide range of therapeutic areas, including cardiovascular, infectious disease, oncology, immunology, central nervous system disorders, and women's healthcare.

Operations

Viatris operates in more than 165 countries and territories around the world. The company has a diverse and balanced business model, with a mix of developed and emerging markets. Viatris has a strong presence in North America, Europe, Asia-Pacific, Middle East and Africa.

Corporate Responsibility

Viatris is committed to corporate responsibility and sustainability. The company's approach to corporate responsibility includes focusing on access to medicines, environmental sustainability, employee health and safety, and ethical governance.

See Also

• Mylan
• Upjohn
• Pfizer
• Pharmaceutical industry

This article is a stub related to pharmacology. You can help WikiMD by expanding it!